Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Revvity (RVTY) reported revenue of $720.28 million for the quarter ended June 2025, reflecting a year-over-year increase of 4.1% [1] - The company's EPS was $1.18, down from $1.22 in the same quarter last year, but exceeded the consensus estimate of $1.14, resulting in an EPS surprise of +3.51% [1] - The revenue surpassed the Zacks Consensus Estimate of $711.27 million, indicating a surprise of +1.27% [1] Revenue and Earnings Performance - Organic revenue growth for the total company was 3%, slightly below the four-analyst average estimate of 3.1% [4] - Organic revenue growth in Life Sciences was 4%, outperforming the 2.2% average estimate from three analysts [4] - Organic revenue growth in Diagnostics was 2%, which fell short of the 3.8% average estimate from three analysts [4] Sales Metrics - Net Sales in Life Sciences reached $365.9 million, exceeding the three-analyst average estimate of $342.32 million, with a year-over-year increase of +16.6% [4] - Net Sales in Diagnostics were reported at $354.39 million, below the three-analyst average estimate of $365.99 million, reflecting a year-over-year decline of -6.3% [4] Stock Performance - Revvity's shares have returned +6% over the past month, outperforming the Zacks S&P 500 composite's +4.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]